Icotinib in Advanced Non-small Cell Lung Cancer (NSCLC) With Hepatic Insufficiency

NCT02062515 ↗

Phase 2 Unknown 30 enrolled Betta Pharmaceuticals Co., Ltd.

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether Icotinib is efficient and safe in treating advanced non-small cell lung cancer (NSCLC) patients with hepatic insufficiency.

Timeline

Start: 2014-02
Primary completion: 2016-02
Completion: 2016-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Icotinib	Small molecule	125 mg	Oral

Icotinib in Advanced Non-small Cell Lung Cancer (NSCLC) With Hepatic Insufficiency

Summary

Timeline

Drugs

Indications